Temporal evolution of dermonecrosis in loxoscelism assessed by photodocumentation

Carla Fernanda Borrasca-Fernandes[1] , Camila Carbone Prado[1] , Eduardo Mello De Capitani[1,2] , Stephen Hyslop[1,3] and Fábio Bucaretchi[1,4]

[1]. Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Centro de Informação e Assistência Toxicológica de Campinas, Campinas, SP, Brasil.
[2]. Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Clínica Médica, Campinas, SP, Brasil.
[3]. Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Medicina Translacional (Área de Farmacologia), Campinas, SP, Brasil.
[4]. Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Pediatria, Campinas, SP, Brasil.

ABSTRACT

Background: Although loxoscelism (bites by brown spiders of the genus *Loxosceles*) frequently results in dermonecrosis, no previous clinical reports have provided detailed temporal photodocumentation of the evolution of dermonecrotic lesions in a case series.

Methods: This was a retrospective cohort study involving a case series of loxoscelism. Only cases of dermonecrosis with photodocumentation of lesion evolution (from admission until complete or almost complete healing) were included.

Results: Eight patients (six men, two women; median age, 38 years) fulfilled the inclusion criteria. The bite sites included the thigh (n = 4), forearm (n = 2), abdomen (n = 1), and trunk (n = 1). Time interval between the bite and first contact with our service ranged from 15 to 216 h (median = 29 h). The main clinical manifestations included local erythematous and ischemic violaceous lesions overlying a base of indurated edema (livedoid plaque, 8), local pain (8), exanthema (6), serohemorrhagic vesicles/blisters (5), fever (5), and jaundice (1). Based on a previously established classification, the cases were classified as probable cutaneous-necrotic loxoscelism (CNL, n = 4), presumptive CNL (n = 3), and presumptive cutaneous-hemolytic loxoscelism (n = 1). Seven patients were treated with anti-arachnidic antivenom (AV; median time post-bite = 46 h). Complete lesion healing ranged from 34 to 98 days post-bite (median, 68 days; six patients). None of the patients required reconstructive plastic surgery.

Conclusions: The sequential photographic documentation showed considerable variation in the process of wound healing, with complete epithelialization requiring up to 3 months after the bite.

Keywords: Antivenom. Brown spider. Dermonecrosis. *Loxosceles* spp. Loxoscelism.

INTRODUCTION

Brown spiders of the genus *Loxosceles* (Heineken and Lowe, 1832) are globally distributed in temperate and tropical regions[1-3]. Bites by *Loxosceles* spp., clinically referred to as loxoscelism, are the main cause of envenomation by spiders of medical importance in Brazil and may result in local dermonecrosis with gravitational spreading (cutaneous-necrotic loxoscelism). On rare occasions, severe systemic complications, such as massive intravascular hemolysis and acute kidney injury (AKI) (cutaneous-hemolytic loxoscelism) may occur. Although at least 19 species of *Loxosceles* have been described in Brazil, most bites occur in southern and southeastern Brazil and are caused by *L. intermedia*, *L. laeta*, and *L. gaucho*[2-4].

Loxoscelism diagnosis is difficult and is rarely based on the identification of the offending spider (<15% of cases in Brazil)[5]. Instead, diagnosis is based on epidemiological data and the known presence of *Loxosceles* spp. in the geographic region where the bite occurred, the patient’s clinical history, and the evolution of local/systemic manifestations[1-7]. Moreover, since at least 40 medical conditions, most of which are dermal infections, may be misdiagnosed as cutaneous-necrotic loxoscelism, Stoecker et al. (2017) developed a useful mnemonic device, referred to as ‘NOT RECLUSE’, that summarizes the typical and atypical findings of skin lesions caused by *L. reclusa* envenomation, the endemic *Loxosceles* species found in the south-central United States[8].

Corresponding author: Dr. Fábio Bucaretchi. e-mail: fbuca@unicamp.br

Authors’ contribution: CFBF: Acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted; CCP: Acquisition of data; EMDC: Acquisition of data, final approval of the version to be submitted; SH: Final revision and approval of the version to be submitted; FB: Conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final revision and approval of the version to be submitted.

Conflict of interest: The authors have no conflict of interest with this work.
In most cases, there is little or no pain associated with the initial envenomation, but algesia increases over time, with bitten individuals generally seeking medical attention 24–48 h post-bite when the cutaneous lesion starts to develop. Clinical indications of cutaneous loxoscelism include the presence of indurated edema under an irregularly demarcated region of ischemic pale skin, mingled with ecchymotic and hemorrhagic tissue that resembles local vasculitis, also known as a livedoid plaque, marble plaque or “white, red, blue/purple sign.” The presence of violaceous discoloration is considered an indication of incipient dermonecrosis\(^5\). The bite region may be associated with a local erythematous plaque, in addition to the presence of vesicles and blisters containing serous or hemorrhagic fluid. These lesions may evolve to dermonecrosis within a few days, with more severe lesions often observed in anatomical areas that have a higher concentration of fatty tissue, such as the thighs, buttocks, and abdomen\(^1\)–\(^7\).

The systemic manifestations associated with cutaneous loxoscelism include flu-like symptoms such as hyperthermia, malaise, headache, and myalgia, in addition to the appearance of local and generalized rashes, primarily as a scarlatiniform (the most common) or morbilliform rash. Patients with intravascular hemolysis may develop complications such as severe anemia, AKI, disseminated intravascular coagulation, rhabdomyolysis, and systemic shock, with some patients requiring a transfusion of red blood cell concentrate and renal replacement therapy\(^6\)–\(^7\).

Despite the high frequency of loxoscelism in North and South America, to our knowledge, no previous clinical reports have provided detailed photodocumentation of the complete course of dermonecrosis (from admission until complete wound healing) in a case series of patients bitten by Loxosceles spp. In view of this limited documentation in clinical literature, in this report, we provide a comprehensive analysis of a case series of loxoscelism in which we use photodocumentation to describe the temporal clinical evolution of the dermal lesions and present the treatments used. These cases were observed and treated in the emergency department (ED) of the university teaching hospital at the State University of Campinas (UNICAMP), Campinas, São Paulo state, southeastern Brazil, and were followed up by the local poison control center (PCC) of the same institution.

**METHODS**

**Patients and data collection**

A retrospective cohort study was performed to evaluate a case series of patients with loxoscelism admitted to our ED from January 2008 to December 2019. Only cases that evolved to dermonecrosis with detailed photodocumentation of lesion evolution (from admission until complete or almost complete healing of the lesion) were included in the study; complete healing was defined based on the contiguity of the cutaneous surface with no exudate\(^6\). Clinical information for each case was retrieved from paper and electronic medical records and was compiled in a specific data system. All patients had their skin lesions photographed during the follow-up. Initial photodocumentation of the lesions was obtained from photographs sent to the PCC during the first call from a health service or patients/relatives, or from photographs taken upon case presentation at our ED. During follow-up, photographs were taken during in-person consultation or sent by the patients using a mobile phone app. All participants in the study provided formal informed consent for the use of the images in publication, and anonymity was guaranteed. This study was approved by the Institutional Committee for Ethics in Research (CEP-UNICAMP, protocol CAAE 97428818.5.0000.5404).

**Clinical classification**

The cases were classified as loxoscelism based on the proposal by Sams et al.\(^9\) in one of the following categories: (1) documented or proven envenomation – offending spider found after bite identified by qualified person, typical lesion, and typical clinical course; (2) probable envenomation – spiders found in the area, patient may have felt the bite, the offending spider was seen, typical lesion, and typical clinical course; and (3) presumptive envenomation – spiders known to occur in the area, compatible lesion, and a typical clinical course. Based on the clinical presentation, patients who developed dermonecrosis only were classified as having cutaneous-necrotic loxoscelism (CNL), while those who developed dermonecrosis and clinical and laboratory features indicative of hemolysis were classified as having cutaneous-hemolytic loxoscelism (CHL)\(^1\)–\(^3\). The spiders were identified to the genus level by co-author FB (physician) using a stereomicroscope to identify the U-shaped arrangement of the three pairs of eyes on the cephalothorax. Species-level identification was performed by an expert arachnologist in the Laboratory for Arthropods at the Instituto Butantan (São Paulo, SP, Brazil).

**Antivenom therapy**

The use of anti-arachnidic antivenom [AV; soro antiaracnídico, Instituto Butantan, Brazil; equine origin; 5 mL/vial containing F(\(\text{ab}^{-}\))\(_2\) antibodies against *Loxosceles gaucho* (brown spider), *Phoneutria nigriventer* (wandering spider) and *Tityus serrulatus* (yellow scorpion) venoms; 1 mL of AV neutralizes 15 minimum necrotizing doses of reference *L. gaucho* venom in rabbits], was based on the Brazilian Ministry of Health guidelines\(^5\)–\(^10\). The current guidelines recommend five vials of AV for patients who develop a severe local lesion, that is, a livedoid plaque with largest dimension > 3 cm, including the surrounding indurated edema, and 10 vials for patients who develop hemolysis\(^10\). The AV was diluted in 0.9% saline and administered intravenously over 30–40 min, without prior medication.

**Data analysis**

For each case, we recorded the relevant information on individual files and on a spreadsheet (Excel, Microsoft Office 2010) prepared for the study; this included sociodemographic data, the spider genus or species (when identified), the local and systemic clinical manifestations of envenomation, time interval between the bite and AV administration, and the procedures used in the topical treatment of the lesions. Demographic and clinical data were tabulated as actual numbers for categorical variables, and as the median and 25th and 75th percentiles (interquartile range, IQR) for continuous variables.

**RESULTS**

**Patient characteristics**

During the study period, 76 patients diagnosed with loxoscelism were admitted to our ED and were monitored by PCC. Based on a detailed review of these cases by two of the authors (CFBF and FB), 68 patients were excluded from further analysis because 36 of them did not develop dermonecrosis and, of the 40 cases that did, 32 had incomplete photographic documentation of the lesion evolution. Thus, only eight cases fulfilled the criterion of complete photodocumentation from admission until complete or almost complete wound healing.
Table 1 summarizes the demographic data of the eight patients and the circumstances of the bites. Six cases involved men, with a median age of 38 years (IQR: 33–49 years), and the time between the bite and the first call to the PCC ranged from 15 to 216 h (median = 29 h, IQR: 22–60 h). Bites occurred on the thigh (4), forearm/arm (2), abdomen (1), and trunk (1). Three patients saw the offending brown spider at the time of the bite, with one of them bringing the offending animal for identification (case 8); however, even with the use of a stereomicroscope, spider identification was not possible because of extensive damage to the specimen. In case 2, a non-offending Loxosceles spp. was found inside the patient’s house, and in case 3, a non-offending brown spider found close to where the patient was bitten was identified as L. gaucho by the Laboratory for Arthropods at the Instituto Butantan (São Paulo, SP, Brazil).

**Clinical findings**

Table 2 summarizes the clinical findings upon admission/evolution and subsequent treatments. Although the bites were initially accompanied by little or no local pain in most cases, in five cases there was a progressive development of pain that was intense by the time of admission, with all the skin lesions evolving to a livedoid plaque with a violaceous discoloration. The largest livedoid plaque dimension was >3 cm in six cases (median = 5 cm), excluding the surrounding indurated edema. Although the size of the lesion in the ischemic area was not assessed upon admission in cases 1 and 4, both developed a livedoid plaque >3 cm (Supplementary Material Figures 1 and 4). In addition, six patients showed erythema, six developed exanthema, and five developed vesicles/blisters. One patient (case 5) developed jaundice 3 days post-bite, with indirect hyperbilirubinemia (3.69 mg/dL; reference value for total bilirubin: 0.3–1.2 mg/dL) and a slight decrease in hemoglobin levels during evolution (admission = 13.3 g/dL; D3 = 11.1 g/dL). There were no changes in coagulation, complement components C3 and C4, and the reticulocyte count, or in the serum aminotransferase, creatinine, total CK, and lactate dehydrogenase activities or levels. Evidence of local skin ulceration was detected 7–26 days post-bite (median = 12 days). None of the patients developed secondary infections. Based on the above features, the eight cases were classified as probable CNL (n = 4), presumptive CNL (n = 3), and presumptive CHL (n = 1) (Tables 1 and 2).

**Antivenom therapy and other treatments**

Seven patients were treated with anti-arachnidic AV (median, 46 h post-bite; IQR: 29–65 h). Topical treatment involved sequential applications of papain (10% and 3%) and mechanical debridement, followed by the application of an oily lotion of essential fatty acids. Two patients were treated with oral prednisone for 5 days, one of whom had CHL (case 5) and the other, with CNL, had uncontrolled itching with no response to histamine H1 antagonists (case 8). Complete lesion healing was observed in six patients (Table 2) and occurred 34–98 days post-bite (median = 68 days; IQR: 55–87 days). None of the patients required reconstructive plastic surgery.

**Photodocumentation of lesion evolution**

Supplementary Material Figures 1-8 provide photographic documentation of the lesion evolution in the eight cases of this series, from the initial admission to the ED onwards. These images illustrate the slow wound healing and skin rash observed in loxoscelism, including the “typical” initial local lesion.

| Case | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Median (IQR) |
|------|---|---|---|---|---|---|---|---|-------------|
| Age (years) | 52 | 19 | 38 | 28 | 52 | 45 | 35 | 37 | 38 (33–49) |
| Sex | M | F | M | F | M | M | M | M | |
| Geographic setting | Rural | Urban | Rural | Urban | Rural | Rural | Urban | Urban | |
| Interval (h) between bite and first contact with the PCC | 20 | 34 | 23 | 40 | 15 | 120 | 216 | 23 | 29 (22–60) |
| Bite site | Right pectoral | Left arm | Right thigh | Right thigh | Left flank | Right thigh | Left forearm | Left thigh | |
| Saw the offending spider | No | No | Yes | No | No | No | No | Yes | No |
| Circumstances of the bite | Sleeping under a tree | Putting on a coat; brought a non-offending brown spider found inside her house | Doing carpentry; brought a non-offending brown spider found close to where he was bitten | Sleeping | Handling a bunch of bananas | Working on a farm | Gardening. Saw a brown spider upon removing his shirt | Hanging clothes on a washing line; brought the offending brown spider | |
| Spider identified | No | Loxosceles spp. | L. gaucho | No | No | No | No | No (spider too damaged to allow identification) | |
| Bite classification | Presumptive CNL | Probable CNL | Probable CNL | Presumptive CNL | Presumptive CNL | Presumptive CNL | Probable CNL | Probable CNL | |

**CNL:** cutaneous necrotic loxoscelism; **CHL:** cutaneous hemolytic loxoscelism; **F:** female; **IQR:** interquartile range; **M:** male; **PCC:** poison control center.
characterized by pale, ischemic, violaceous areas (livedoid plaque; Supplementary Material Figure 2, D2 and D3), a livedoid plaque and local spreading edema (Supplementary Material Figure 1, D2), a generalized scarlatiniform rash with blanching in response to digital pressure (Supplementary Material Figures 1 and 8, D2), a livedoid plaque with serohemorrhagic vesicles surrounded by a large erythematous plaque evolving with serohemorrhagic blisters (Supplementary Material Figure 4, D5–D11), a large ischemic violaceous area surrounded by a pale halo (Supplementary Material Figure 7, D9–D15), and an ischemic lesion with confluent ulcerations (Supplementary Material Figure 5, D10). Additionally, we documented the progression of the ischemic lesion to ulceration with well-defined borders (Supplementary Material Figure 6, D9–D45), the presence of granular tissue during the wound healing of a large lesion (Supplementary Material Figure 7, D57–D64), and the lesion appearance at various times (2 months to 8 years) after local lesion healing in cases 2 and 5–8 (Supplementary Material Figure 9).

Hypochromic scars were observed in cases 2, 5, and 6, while case 7 showed a hypertrophic scar; tissue retraction occurred in case 8.

**DISCUSSION**

Although 53% of the 76 cases of loxoscelism admitted to our ED during the study period developed dermonecrosis, complete photodocumentation of the evolution of dermonecrosis until complete or almost complete wound healing was available for only eight patients, who were included in this study. The frequency of dermonecrosis in the patients admitted to our ED with loxoscelism was similar to previous reports from three large case series' in the Brazilian states of Santa Catarina (1985–1996, n = 267, within the geographic range of *L. laeta*11 and São Paulo (1985–1996, n = 359, 2004–2006, n = 81; both within the geographic range of *L. gaucho*), which reported dermonecrosis in 53–58% of cases12,13. In contrast, the frequency of massive hemolysis was higher in Santa Catarina (13%) than in São Paulo (3–4%), indicating more severe envenomation by *L. laeta*11,12. However, Málaque et al.13 suggested that the frequency of hemolysis in loxoscelism in geographic regions where *L. gaucho* predominates may be higher than what has been previously reported, when this manifestation is analyzed based on the increased serum levels of indirect bilirubin and reticulocyte counts; based on these criteria, the authors reported a frequency of hemolysis of up to 31%.

As mentioned in the Introduction, the diagnosis of loxoscelism is rarely based on identification of the offending spider, as reported here. Based on the NOT RECLUSE mnemonic device8, all patients in the present case series fulfilled the clinical criteria for the diagnosis of probable/presumptive loxoscelism1. The time required for healing (within 3 months post-bite; median = 68 days) was similar to that of patients who developed more intense dermonecrosis, that is, skin necrosis > 1 cm2 (grade 3, mean = 74 days)9.

Sphingomyelinase D is the most important toxin involved in dermonecrosis and intravascular hemolysis14,15. This toxin activates the complement cascade, polymorphonuclear cells and platelets, in addition to inducing the expression of metalloproteinases in rabbits and human keratinocytes; metalloproteinases contribute to dermonecrosis, whereas lesion expansion or spreading is attributed

---

**TABLE 2:** Clinical findings upon admission/evolution and the treatment given in eight cases of dermonecrotic loxoscelism.

| Case | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | N | Median (IQR) |
|------|---|---|---|---|---|---|---|---|---|---------------|
| Local |   |   |   |   |   |   |   |   |   |               |
| Pain | Intense | Moderate | Intense | Mild | Intense | Mild | Intense | Intense | 8 |               |
| Indurated edema | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8               |
| Livedoid plaque | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8               |
| Size (cm/d)* | NM | 5 | 4 | NM | 6 | 5 | 15 | 4 | 6 | 5 (4–6)         |
| Erythema | Yes | Yes | Yes | Yes | No | Yes | No | Yes | 6 |               |
| Vesicles/blisters | No | No | Yes | Yes | Yes | No | Yes | Yes | 5 |               |
| Skin ulceration (Days post-bite) | 12 | 16 | 12 | 12 | 7 | 9 | 26 | 11 | 8 | 12 (11–13)     |

| Systemic |   |   |   |   |   |   |   |   |   |               |
| Exanthema | Trunk | Abdomen, thighs, and pelvis | Thighs | Lower members | No | Trunk and thigh | No | Generalized | 6 |               |
| Others | Fever | Fever and malaise | Fever | Fever and headache | Jaundice, dark urine, and malaise | NR | Shivering and tremors | Fever, paresthesia (hands and feet), and generalized itching | 7 |               |
| Antivenom |   |   |   |   |   |   |   |   |   |               |
| Hours post-bite | 27 | 46 | 30 | 49 | 81 | 124 | No AV used | 25 | 7 | 46 (29–65) |
| Number of vials | 5 | 4 | 5 | 5 | 5 | 5 | - | 5 | 7 | 5 (5–5) |
| Oral prednisone | No | Yes | No | No | No | Yes | No | No | Yes | 2               |
| Topical |   |   |   |   |   |   |   |   |   |               |
| Papain | No | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | 6               |
| EFAL | No | Yes | No | Yes | No | Yes | Yes | No | Yes | 4               |
| Mechanical debridement | No | Yes | No | Yes | Yes | No | Yes | No | 4               |
| Healing time (Days post-bite) | 34 | 91 | ACWH (20) | 53 | 74 | ACWH (60) | 98 | 61 | 68 (55–87) |

ACWH: almost complete wound healing; AV: anti-arachnidic antivenom; EFAL: essential fatty acid lotion; IQR: interquartile range; NM: not measured; NR: not reported.

* Largest dimension of the ischemic area (livedoid plaque) upon admission, excluding the surrounding indurated edema.
to the action of hyaluronidase. Sphingomyelinase D-induced metalloproteinases cleave red blood cell surface glycoporphins, leading to hemolysis and the release of hemoglobin into the general circulation.14,15.

Biopsies of necrotic tissue after Loxosceles spp. bites in humans have revealed the presence of indurated edema and an inflammatory infiltrate composed predominantly of polymorphonuclear leukocytes, as well as local thrombosis, hemorrhage, and liquefactive necrosis of the dermis and epidermis, similar to that described in pyoderma gangrenosum. Similar lesions have been reproduced in animal models, such as rabbits. However, the temporal evolution of histopathological alterations in rabbits indicates faster development and spreading of cutaneous necrosis than that in humans, with cutaneous necrosis being detected at the site of venom inoculation within 24 h post-venom injection; in humans, ulceration usually starts 7–14 days post-envenomation. In the case series examined here, the earliest skin ulceration was detected 7 days post-bite (median, 12 days).

Based on the current guidelines for the diagnosis and clinical treatment of loxoscelism in Brazil,19 seven patients were treated with anti-arachnidic AV, with the earliest treated patient (case 8) receiving AV 25 h post-bite. No AV was administered in case 7 since the patient only sought the ED 9 days after the bite. Overall, the time between the bite and AV administration was very similar to the median of 48 h reported by Malaque et al.13

Anti-arachnidic AV has been used to treat loxoscelism in Brazil since the 1960s and shows good neutralizing potency against the dememecrosis and lethality of various Loxosceles spp. venoms in rabbits. However, doubts remain regarding its efficacy in neutralizing the local and systemic effects of loxoscelism in humans, what the most appropriate time for post-envenomation AV administration is, and the length of administration. Of relevance in this regard is the length of time that venom persists at the site of inoculation. Based on enzyme-linked immunosorbent assay (ELISA), Loxosceles spp. venoms have been shown to remain at the bite site for a considerable time after inoculation. Cardoso et al.17 reported two cases, one involving a 72-year-old woman and another of a 20-month-old girl, in which venom was detectable in necrotic skin lesions 5 and 29 days after the bite, respectively. In addition, an experimental study in rabbits demonstrated that L. reclusa venom and sphingomyelinase D were detectable at the site of injection 14–21 days after injection.18

Experimental studies in rabbits have shown that when a specific anti-Loxosceles AV produced by the Centro de Produção e Pesquisa de Imunobiológicos do Paraná (equine origin, Fab’), 1 mL neutralizes 15 minimum necrotic doses of the venom of L. gaucho, L. laeta, and L. intermedia in rabbits and available for use in southern Brazil is administered intravenously 6 h, 12 h, 24 h, and 48 h post-venom, the extent of dememecrosis induced by two minimum necrotic doses of L. intermedia venom (equivalent to 16 µg of venom) is significantly reduced. The greatest effect was observed in rabbits injected with AV 6 h after envenomation (90% reduction in the size of the dememecrotic lesion when compared to the controls).19

Although controversal, the use of corticosteroids either orally, such as prednisone (40–60 mg/day/5–7 days) or parenterally (intravenous hydrocortisone or prednisolone), has been recommended for the treatment of CHL in some countries, for example, Brazil, Chile, and USA. In addition, despite the lack of clear clinical evidence of a beneficial effect, a 5- to 7-day course of oral prednisone has been recommended for the treatment of CNL in Brazil since 2014 for patients who develop a livedoid plaque. In contrast, a multivariate analysis of the clinical outcome (diameter of the necrotic area and time to heal) in a prospective series of 189 patients with loxoscelism in Oklahoma (USA, 1995–2000) revealed no significant difference between patients treated systemically with corticosteroids (n = 76) compared with non-treated patients (n = 113). However, the type of corticosteroids used and the dosage scheme were not clearly indicated in this report, nor was there a clear statement of the time after the bite when the treatment was initiated. The foregoing discussion indicates that there is clearly a need for robust clinical trials to formally assess the efficacy of AV and corticosteroids in the treatment of loxoscelism.

The topical treatments used in this study were based on the general recommendations of the university hospital’s wound treatment group, with the general aim of preventing secondary infections, stimulating angiogenesis, and accelerating wound healing. However, because of inherent limitations in the study design, it was not possible to rigorously assess whether topical treatment influenced the process of wound healing. A potentially useful novel approach for treating venom-induced local effects involves drug repurposing, specifically the topical application of tetracycline in the case of loxoscelism. Experimental studies in rabbits have shown that the topical application of a cream containing lanolin and 5% tetracycline for up to 6 h after the injection of L. intermedia venom or recombinant sphingomyelinase D significantly reduced the local production of matrix metalloproteinases MPP-2 and MPP-9 and the progression of dememecrosis. These findings suggest that tetracycline could be a potentially useful drug for treating cutaneous loxoscelism, but this remains to be assessed in formal clinical trials in humans.

The present study has several limitations, including the type of study (retrospective cohort), the small number of patients examined that reflected the strict inclusion criterion of complete photodocumentation of the case until healing or almost complete healing, and possible bias in patient selection because of this criterion. Despite these limitations, this case series provides a useful record of complete sequential photographic documentation of loxoscelism from initial admission until complete wound healing. The results indicate considerable variation in the process of wound healing, with complete epithelialization requiring up to 3 months post-bite. Despite the use of AV and rigorous treatment and care of the local lesions, all patients showed permanent local scarring of varying intensity that involved hypochromic and hypertrophic scars.

ACKNOWLEDGMENTS

The authors thank Dr. Rogério Bertani (Laboratory for Arthropods, Instituto Butantan, São Paulo, SP, Brazil) for identifying the spiders.

REFERENCES

1. Hogan CJ, Barbaro KC, Winkel K. Loxoscelism: old obstacles, new directions. Ann Emerg Med. 2004;44(6):608–24.

2. Malaque CMS, Chaim OM, Entreis M, Barbaro KC. Loxosceles and loxoscelism: biology, venom, envenomation, and treatment. In: Gopalakrishnakone P, Corzo G, de Lima MH, Diego-García E, editors. Spider venoms. Dordrecht: Springer Nature; 2016. p. 419–44.

3. Lopes PH, Squaiella-Baptistão CC, Marques MOT, Tambourgi DV. Clinical aspects, diagnosis and management of Loxosceles spider venoms. Dordrecht: Springer Nature; 2016. p. 419–44.
envenomation: literature and case review. Arch Toxicol. 2020;94(5):1461-77.

4. da Silva PH, da Silveira RB, Appel MH, Mangili OC, Gremski W, Veiga SS. Brown spiders and loxoscelism. Toxicon. 2004;44(7):693-709.

5. Sams HH, Dunnick CA, Smith ML, King LE Jr. Necrotic arachnidism. J Am Acad Dermatol. 2001;44(4):561-73.

6. Sams HH, Heath SB, Long LL, Wilson DC, Sanders DH, King LE Jr. Nineteen documented cases of *Loxosceles reclusa* envenomation. J Am Acad Dermatol. 2001;44(4):603-8.

7. Swanson DL, Vetter RS. Loxoscelism. Clin Dermatol. 2006;24(3):213-21.

8. Stoecker WV, Vetter RS, Dyer JA. Not reclassify – a mnemonic device to avoid false diagnoses of brown recluse spider bites. JAMA Dermatol. 2017;153(5):377-8.

9. Ministério da Saúde (MS). Fundação Nacional de Saúde - Manual de Diagnóstico e Tratamento de Acidentes por Animais Peçonhentos. 1st edition, Brasília: MS, DF; 1998. 112 p.

10. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde - Protocolos clínicos. Acidente por aranha do gênero *Loxosceles*, 2014. Available from: [http://www.dive.sc.gov.br/conteudos/agravos/publicacoes/ProtocoloClinicoAcidenteAranhaLoxosceles2014.pdf](http://www.dive.sc.gov.br/conteudos/agravos/publicacoes/ProtocoloClinicoAcidenteAranhaLoxosceles2014.pdf). Accessed on July 6, 2021.

11. Sezerino UM, Zannin M, Coelho LK, Gonçalves Júnior J, Grando M, Mattosinho SG, et al. A clinical and epidemiological study of *Loxosceles* spider envenoming in Santa Catarina, Brazil. Trans R Soc Trop Med Hyg. 1998;92(5):546-8.

12. Málaga CM, Castro-Valencia JE, Cardoso JL, França FO, Barbaro KC, Fan HW. Clinical and epidemiological features of definitive and presumed loxoscelism in São Paulo, Brazil. Rev Inst Med Trop São Paulo. 2002;44(3):139-43.

13. Málaga CM, Santoro ML, Cardoso JL, Conde MR, Novaes CT, Risk JY, et al. Clinical picture and laboratory evaluation in human loxoscelism. Toxicon. 2011;58(8):664-71.

14. Tambourgi DV, Paixão-Cavalcante D, Gonçalves-de-Andrade RM, Fernandes-Pedrosa MF, Magnoli FC, Paul Morgan B, et al. *Loxosceles* sphingomyelinase induces complement-dependent dermonecrosis, neutrophil infiltration, and endogenous gelatinase expression. J Invest Dermatol. 2005;124(4):725-31.

15. Tambourgi DV, Gonçalves-de-Andrade RM, van den Berg CW. Loxoscelism: from basic research to the proposal of new therapies. Toxicon. 2010;56(7):1113-9.

16. Pauli I, Puka J, Gubert IC, Minozzo JC. The efficacy of antivenom in loxoscelism treatment. Toxicon. 2006;48(2):123-37.

17. Cardoso JL, Wen FH, França FO, Warrell DA, Theakston RD. Detection by enzyme immunoassay of *Loxosceles gaucho* venom in necrotic skin lesions caused by spider bites in Brazil. Trans R Soc Trop Med Hyg. 1999;84(4):608-9.

18. McGlasson DL, Green JA, Stoecker WW, Babcock JL, Calcar DA. Duration of *Loxosceles reclusa* venom detection by ELISA from swabs. Clin Lab Sci. 2009;22(4):216-22.

19. Pauli I, Minozzo JC, da Silva PH, Chaim OM, Veiga SS. Analysis of therapeutic benefits of antivenin at different time intervals after experimental envenomation in rabbits by venom of the brown spider (*Loxosceles intermedia*). Toxicon. 2009;53(6):660-71.

20. Ministerio de la Salud. Gobierno de Chile. Departamento de Enfermedades Transmisibles División de Prevención y Control de Enfermedades - Guía clínica para el manejo de mordedura de araña de los rincones – *Loxosceles laeta*. Santiago: Ministerio de Salud; 2016. 16 p. Available from: [https://www.minsal.cl/wp-content/uploads/2016/11/LOXOSCELES-FINAL.pdf](https://www.minsal.cl/wp-content/uploads/2016/11/LOXOSCELES-FINAL.pdf). Accessed on July 6, 2021.

21. Mold JW, Thompson DM. Management of brown recluse spider bites in primary care. J Am Board Fam Pract. 2004;17(5):347-52.

22. Paixão-Cavalcante D, van den Berg CW, Gonçalves-de-Andrade RM, Fernandes-Pedrosa MF, Okamoto CK, Tambourgi DV. Tetracycline protects against demonecrosis induced by *Loxosceles* spider venom. J Invest Dermatol. 2007;127(6):1410-8.

Received 22 August 2021 | Accepted 23 November 2021